Multivalent CD20-binding molecule comprising Shiga toxin A subunit effector polypeptides and enriched compositions thereof
Provided herein are multivalent CD20-binding molecules, and compositions thereof, for use in selective killing of specific cell types and/or as therapeutics for the treatment of a variety of diseases, including cancer, tumors, and immune disorders. Certain multivalent CD20-binding molecules can be used to deliver agents into CD20-expressing cells, collecting diagnostic information, and/or monitoring the treatment of diseases, such as cancers, tumors, and immune disorders.
1. A multivalent CD20-binding molecule comprising two polypeptides associated through one or more cysteine disulfide bonds, wherein each polypeptide comprises:
a) one or more CD20 binding region comprising a single-chain variable fragment that is capable of specifically binding an extracellular part of a CD20; wherein the CD20 binding region comprises:
i) a heavy chain variable (VH) domain polypeptide comprising HCDR1, HCDR2, and HCDR3 amino acid sequences as shown in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively, and a light chain variable (VL) domain polypeptide comprising LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, respectively;
ii) a heavy chain variable (VH) domain polypeptide comprising HCDR1, HCDR2, and HCDR3 amino acid sequences as shown in SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13, respectively, and a light chain variable (VL) domain polypeptide comprising LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, respectively;
iii) a heavy chain variable (VH) domain polypeptide comprising HCDR1, HCDR2, and HCDR3 amino acid sequences as shown in SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19, respectively, and a light chain variable (VL) domain polypeptide comprising LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22, respectively;
iv) a heavy chain variable (VH) domain polypeptide comprising HCDR1, HCDR2, and HCDR3 amino acid sequences as shown in SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25, respectively, and a light chain variable (VL) domain polypeptide comprising LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28, respectively;
v) a heavy chain variable (VH) domain polypeptide comprising HCDR1, HCDR2, and HCDR3 amino acid sequences as shown in SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31, respectively, and a light chain variable (VL) domain polypeptide comprising LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in SEQ ID NO: 32, SEQ ID NO: 33, and SEQ ID NO: 34, respectively; or
vi) a heavy chain variable (VH) domain polypeptide comprising HCDR1, HCDR2, and HCDR3 amino acid sequences as shown in SEQ ID NO: 35, SEQ ID NO: 36, and SEQ ID NO: 37, respectively, and a light chain variable (VL) domain polypeptide comprising LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40, respectively; and
b) one or more Shiga toxin A subunit effector polypeptides comprising an amino acid sequence that is at least 95% identical to an amino acid sequence selected from:
(a) amino acids 75 to 251 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3;
(b) amino acids 1 to 241 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3;
(c) amino acids 1 to 251 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; and
(d) amino acids 1 to 261 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3;
wherein the amino acid residue corresponding to position 75 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is asparagine, the amino acid residue corresponding to position 77 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is tyrosine, the amino acid residue corresponding to position 167 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is glutamate, the amino acid residue corresponding to position 170 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is arginine, and the amino acid residue corresponding to position 176 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is arginine;
wherein the Shiga toxin effector polypeptide is capable of exhibiting at least one Shiga toxin function.
2. The multivalent CD20-binding molecule of claim 1 , wherein administration of the multivalent CD20-binding molecule to a CD20 positive cell results in one or more of:
i) internalizing the multivalent CD20-binding molecule inside the cell, optionally within five hours, four hours, three hours, two hours, one hour, or thirty minutes at about 37 degrees Celsius;
ii) subcellular routing a Shiga toxin A subunit effector polypeptide to the cell's cytosol;
iii) disrupting a ribosome function within the cell; and
iv) killing of the cell.
3. The multivalent CD20-binding molecule of claim 1 , which comprises:
(a) two polypeptides, each having the amino acid sequence of any one of SEQ ID NOs: 47-175 and 294, and each polypeptide optionally further comprising an amino-terminal methionine residue; and
(b) a cysteine disulfide bond linking the two polypeptides, wherein the cysteine disulfide bond involves a cysteine residue in each of the two polypeptides located at amino acid position:
(i) 242 for polypeptides having the amino acid sequence of SEQ ID NOs: 120-175, or 294;
(ii) 482 for polypeptides having the amino acid sequence of SEQ ID NOs: 100, 105, or 107;
(iii) 483 for polypeptides having the amino acid sequence of SEQ ID NOs: 62 or 74;
(iv) 484 for polypeptides having the amino acid sequence of SEQ ID NOs: 79 or 86;
(v) 490 for the polypeptide having the amino acid sequence of SEQ ID NO: 49;
(vi) 491 for the polypeptide having the amino acid sequence of SEQ ID NO: 51;
(vii) 492 for polypeptides having the amino acid sequence of SEQ ID NOs: 56, 68, 91, 99, 103, or 104;
(viii) 493 for polypeptides having the amino acid sequence of SEQ ID NOs: 58, 70 or 81;
(ix) 494 for polypeptides having the amino acid sequence of SEQ ID NOs: 112 or 118;
(x) 495 for the polypeptide having the amino acid sequence of SEQ ID NO: 113;
(xi) 499 for the polypeptide having the amino acid sequence of SEQ ID NO: 52;
(xii) 500 for the polypeptide having the amino acid sequence of SEQ ID NO: 48;
(xiii) 501 for polypeptides having the amino acid sequence of SEQ ID NOs: 50, 61, 73, 96, 101, or 102;
(xiv) 502 for polypeptides having the amino acid sequence of SEQ ID NOs: 55, 64, 67, 76, 90, 92, 93, 97, or 98;
(xv) 503 for polypeptides having the amino acid sequence of SEQ ID NOs: 54, 57, 69, 78, 82, 84, 87, 88, 94, 110, 111, or 115;
(xvi) 504 for polypeptides having the amino acid sequence of SEQ ID NOs: 85, 108, or 114;
(xvii) 505 for the polypeptide having the amino acid sequence of SEQ ID NO: 119;
(xviii) 510 for the polypeptide having the amino acid sequence of SEQ ID NO: 47;
(xix) 511 for polypeptides having the amino acid sequence of SEQ ID NOs: 60, 72, or 106;
(xx) 512 for polypeptides having the amino acid sequence of SEQ ID NOs: 53, 63, 66, 75, 83, 89, or 95;
(xxi) 513 for polypeptides having the amino acid sequence of SEQ ID NOs: 80, 109, 116, or 117; or
(xxii) 521 for polypeptides having the amino acid sequence of SEQ ID NOs: 59, 65, 71, or 77.
4. The multivalent CD20-binding molecule of claim 3 , which is a homodimer and consists essentially of:
(a) two identical polypeptides each having the amino acid sequence selected from any one of SEQ ID NOs: 47-175 and 294; and
(b) a cysteine disulfide bond linking the two identical polypeptides, wherein the cysteine disulfide bond involves a cysteine residue in each of the two identical polypeptides located at amino acid position:
(i) 242 for polypeptides having the amino acid sequence of SEQ ID NOs: 120-175, or 294;
(ii) 482 for polypeptides having the amino acid sequence of SEQ ID NOs: 100, 105, or 107;
(iii) 483 for polypeptides having the amino acid sequence of SEQ ID NOs: 62 or 74;
(iv) 484 for polypeptides having the amino acid sequence of SEQ ID NOs: 79 or 86;
(v) 490 for the polypeptide having the amino acid sequence of SEQ ID NO: 49;
(vi) 491 for the polypeptide having the amino acid sequence of SEQ ID NO: 51;
(vii) 492 for polypeptides having the amino acid sequence of SEQ ID NOs: 56, 68, 91, 99, 103, or 104;
(viii) 493 for polypeptides having the amino acid sequence of SEQ ID NOs: 58, 70 or 81;
(ix) 494 for polypeptides having the amino acid sequence of SEQ ID NOs: 112 or 118;
(x) 495 for the polypeptide having the amino acid sequence of SEQ ID NO: 113;
(xi) 499 for the polypeptide having the amino acid sequence of SEQ ID NO: 52;
(xii) 500 for the polypeptide having the amino acid sequence of SEQ ID NO: 48;
(xiii) 501 for polypeptides having the amino acid sequence of SEQ ID NOs: 50, 61, 73, 96, 101, or 102;
(xiv) 502 for polypeptides having the amino acid sequence of SEQ ID NOs: 55, 64, 67, 76, 90, 92, 93, 97, or 98;
(xv) 503 for polypeptides having the amino acid sequence of SEQ ID NOs: 54, 57, 69, 78, 82, 84, 87, 88, 94, 110, 111, or 115;
(xvi) 504 for polypeptides having the amino acid sequence of SEQ ID NOs: 85, 108, or 114;
(xvii) 505 for the polypeptide having the amino acid sequence of SEQ ID NO: 119;
(xviii) 510 for the polypeptide having the amino acid sequence of SEQ ID NO: 47;
(xix) 511 for polypeptides having the amino acid sequence of SEQ ID NOs: 60, 72, or 106;
(xx) 512 for polypeptides having the amino acid sequence of SEQ ID NOs: 53, 63, 66, 75, 83, 89, or 95;
(xxi) 513 for polypeptides having the amino acid sequence of SEQ ID NOs: 80, 109, 116, or 117; or
(xxii) 521 for polypeptides having the amino acid sequence of SEQ ID NOs: 59, 65, 71, or 77.
5. The multivalent CD20-binding molecule of claim 4 , wherein the two identical polypeptides each have the amino acid sequence shown in SEQ ID NO:49; and wherein the disulfide bond is between cysteine residues at amino acid position 490.
6. The multivalent CD20-binding molecule of claim 4 , wherein the two identical polypeptides each have the amino acid sequence shown in any one of SEQ ID NO: 50, SEQ ID NO: 61, SEQ ID NO: 73, SEQ ID NO: 96, SEQ ID NO: 101, or SEQ ID NO: 102; and wherein the disulfide bond is between cysteine residues at amino acid position 501.
7. The multivalent CD20-binding molecule of claim 4 , wherein the two identical polypeptides each have the amino acid sequence selected from any one of SEQ ID NO: 53, SEQ ID NO: 63, SEQ ID NO: 66, SEQ ID NO: 75, SEQ ID NO: 83, SEQ ID NO: 89, or SEQ ID NO: 95; and wherein the disulfide bond is between cysteine residues at amino acid position 512.
8. The multivalent CD20-binding molecule of claim 4 , wherein the two identical polypeptides each have the amino acid sequence shown in SEQ ID NO: 54; and wherein the disulfide bond is between cysteine residues at amino acid position 503.
9. The multivalent CD20-binding molecule of claim 4 , wherein the two identical polypeptides each have the amino acid sequence selected from any one of SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 67, SEQ ID NO: 76, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 97, or SEQ ID NO: 98; and wherein the disulfide bond is between cysteine residues at amino acid position 502.
10. The multivalent CD20-binding molecule of claim 4 , wherein the two identical polypeptides each have the amino acid sequence selected from any one of SEQ ID NO: 56, SEQ ID NO: 68, SEQ ID NO: 91, SEQ ID NO: 99, SEQ ID NO: 103, or SEQ ID NO: 104; and wherein the disulfide bond is between cysteine residues at amino acid position 492.
11. The multivalent CD20-binding molecule of claim 4 , wherein the two identical polypeptides each have the amino acid sequence selected from any one of SEQ ID NO: 57, SEQ ID NO: 69, SEQ ID NO: 78, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 94, SEQ ID NO: 110, SEQ ID NO: 111, or SEQ ID NO: 115; and wherein the disulfide bond is between cysteine residues at amino acid position 503.
12. The multivalent CD20-binding molecule of claim 4 , wherein the two identical polypeptides are selected from any one of SEQ ID NO: 58, SEQ ID NO: 70, or SEQ ID NO: 81; and wherein the disulfide bond is between cysteine residues at amino acid position 493.
13. The multivalent CD20-binding molecule of claim 4 , wherein the two identical polypeptides each have the amino acid sequence of SEQ ID NO: 294, and wherein the disulfide bond is between cysteine residues at amino acid position 242.
14. A composition comprising the multivalent CD20-binding molecule of claim 1 , wherein the composition comprises a ratio of monovalent CD20-binding molecule concentration to total CD20-binding molecule concentration of less than one to three, wherein each monovalent CD20-binding molecule
comprises only one CD20 binding region capable of specifically binding an extracellular part of a CD20; and
comprises a Shiga toxin effector A subunit polypeptide.
15. The composition of claim 14 , wherein the ratio of monovalent CD20-binding molecule concentration to total CD20-binding molecule concentration is less than: 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, or 1:11.
16. A pharmaceutical composition comprising the multivalent CD20-binding molecule of claim 1 and at least one pharmaceutically acceptable excipient or carrier.
17. The pharmaceutical composition of claim 16 , wherein the excipient is:
acetate, alcohol, alpha-tocopherol, aluminum monostearate, ascorbic acid, ascorbyl palmitate, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, chlorobutanol, citrate, cysteine hydrochloride, dextrose, ethanol, ethylenediaminetetraacetic acid, ethyloleate, gelatin, glycerine, glycerol, lactic acid, lecithin, mannitol, methyl parabens, monostearate salt, organic ester, paraben, phenol phosphate, phosphoric acid, polyalcohol, polyethylene glycol, polyol, propylene glycol, propylgallate, sodium bisulfate, sodium bisulfite, sodium chloride, sodium metabisulfite, sodium sulfite, sorbic acid, sorbitol, sugar, tartaric acid, or vegetable oil.
18. A kit comprising:
the multivalent CD20-binding molecule of claim 1 ; and an additional reagent and/or pharmaceutical delivery device.
19. The multivalent CD20-binding molecule of claim 1 , wherein the Shiga toxin A subunit effector polypeptide comprises a polypeptide sequence selected from:
(a) amino acids 75 to 251 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3;
(b) amino acids 1 to 241 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3;
(c) amino acids 1 to 251 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; and
(d) amino acids 1 to 261 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
20. A multivalent CD20-binding molecule comprising two monovalent polypeptides associated through one or more cysteine disulfide bonds, each polypeptide comprising:
a) a CD20 binding region comprising a single-chain variable fragment that is capable of specifically binding an extracellular part of a CD20; wherein the CD20 binding region comprises:
i) a heavy chain variable (VH) domain polypeptide comprising HCDR1, HCDR2, and HCDR3 amino acid sequences as shown in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively, and a light chain variable (VL) domain polypeptide comprising LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, respectively;
ii) a heavy chain variable (VH) domain polypeptide comprising HCDR1, HCDR2, and HCDR3 amino acid sequences as shown in SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13, respectively, and a light chain variable (VL) domain polypeptide comprising LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, respectively;
iii) a heavy chain variable (VH) domain polypeptide comprising HCDR1, HCDR2, and HCDR3 amino acid sequences as shown in SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19, respectively, and a light chain variable (VL) domain polypeptide comprising LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22, respectively;
iv) a heavy chain variable (VH) domain polypeptide comprising HCDR1, HCDR2, and HCDR3 amino acid sequences as shown in SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25, respectively, and a light chain variable (VL) domain polypeptide comprising LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28, respectively;
v) a heavy chain variable (VH) domain polypeptide comprising HCDR1, HCDR2, and HCDR3 amino acid sequences as shown in SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31, respectively, and a light chain variable (VL) domain polypeptide comprising LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in SEQ ID NO: 32, SEQ ID NO: 33, and SEQ ID NO: 34, respectively; or
vi) a heavy chain variable (VH) domain polypeptide comprising HCDR1, HCDR2, and HCDR3 amino acid sequences as shown in SEQ ID NO: 35, SEQ ID NO: 36, and SEQ ID NO: 37, respectively, and a light chain variable (VL) domain polypeptide comprising LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40, respectively;
and
b) a Shiga toxin A subunit effector polypeptide comprising an amino acid sequence that is at least 95% identical to an amino acid sequence selected from:
(i) amino acids 75 to 251 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3;
(ii) amino acids 1 to 241 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3;
(iii) amino acids 1 to 251 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; and
(iv) amino acids 1 to 261 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3;
wherein the amino acid residue corresponding to position 75 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is asparagine, the amino acid residue corresponding to position 77 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is tyrosine, the amino acid residue corresponding to position 167 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is glutamate, the amino acid residue corresponding to position 170 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is arginine, and the amino acid residue corresponding to position 176 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is arginine;
wherein the Shiga toxin effector polypeptide is capable of effectuating Shiga toxin A subunit cytotoxicity; and
wherein upon administration of the multivalent CD20-binding molecule to a population of CD20 positive cells expressing CD20 which have the extracellular part of CD20 bound by the two or more CD20 binding regions, the multivalent CD20-binding molecule exhibits a cytotoxic effect which is greater than a cytotoxic effect resulting from administration of an equivalent amount, mass, or molarity of any one of the monovalent CD20-binding components of the multivalent CD20-binding molecule to a population of the same CD20 positive cells under the same conditions; wherein the cytotoxic effect is:
(i) greater by a factor of at least 1.33; or
(ii) greater than the change in CD20-binding valence between the monovalent CD20-binding component and the multivalent CD20-binding molecule.
21. The multivalent CD20-binding protein of claim 1 , wherein the one or more Shiga toxin A subunit effector polypeptides comprises a sequence that is at least 98% identical to an amino acid sequence selected from:
(a) amino acids 75 to 251 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3;
(b) amino acids 1 to 241 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3;
(c) amino acids 1 to 251 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; and
(d) amino acids 1 to 261 of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.
22. The multivalent CD20-binding protein of claim 1 , comprising two identical polypeptides linked by at least one covalent bond, each polypeptide having at least 98% sequence identity to an amino acid sequence shown in SEQ ID NO: 54; wherein the covalent bond is a cysteine disulfide bond between cysteine residues at amino acid position 503.
23. The multivalent CD20-binding protein of claim 1 , comprising two identical polypeptides linked by at least one covalent bond, each polypeptide having at least 98% sequence identity to an amino acid sequence shown in SEQ ID NO: 55; wherein the covalent bond is a cysteine disulfide bond between cysteine residues at amino acid position 502.